Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications
Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: July 26, 2017
Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia.
Journal: Blood
Published: April 13, 2017
Subsequent primary malignancies among multiple myeloma patients treated with or without lenalidomide.
Journal: Leukemia & lymphoma
Published: July 19, 2016
Connect MM® - the Multiple Myeloma Disease Registry: incidence of second primary malignancies in patients treated with lenalidomide.
Journal: Leukemia & lymphoma
Published: January 15, 2016
Subsequent primary malignancies and acute myelogenous leukemia transformation among myelodysplastic syndrome patients treated with or without lenalidomide.
Journal: Cancer medicine
Published: January 13, 2016
Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS.
Journal: Leukemia
Published: December 10, 2015
Evaluation of pharmacokinetic and pharmacodynamic interactions when lenalidomide is co-administered with warfarin in a randomized clinical trial setting.
Journal: Clinical drug investigation
Published: May 31, 2015
Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma.
Journal: The New England journal of medicine
Published: September 04, 2014
Pomalidomide is teratogenic in rats and rabbits and can be neurotoxic in humans.
Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: December 05, 2013
Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS.
Journal: Leukemia
Published: June 04, 2013
Mature results of MM-011: a phase I/II trial of liposomal doxorubicin, vincristine, dexamethasone, and lenalidomide combination therapy followed by lenalidomide maintenance for relapsed/refractory multiple myeloma.
Journal: American journal of hematology
Published: May 17, 2013
Last Updated: 09/26/2026